Median In-Network Rates for Keytruda across Select BUCA Payers, July 2024 to July 2025
Median in-network commercial rates for Keytruda (pembrolizumab), based on Transparency in Coverage data released by U.S. commercial payers in July 2024 and July 2025 and compiled by Serif Health. Estimates reflect median negotiated payment amounts associated with HCPCS code J9271 and assume standard per treatment dosing of 200 mg. Data are limited to relevant providers, exclude per diem and percentage-based observations, and represent allowed amounts contracted between payers and billing providers (EINs). Payer-level medians summarize pricing across covered networks and providers across networks compiled by Serif Health.